Results 161 to 170 of about 56,171 (221)

Correction: Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein. [PDF]

Mol Neurodegener
Liang J, Li R, Wong G, Huang X.
europepmc   +1 more source

Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes. [PDF]

Alzheimers Dement
Liu S, Yang S, Sui Y.
europepmc   +1 more source

Early functional changes in lewy body dementia: roles of dynamics, locus coeruleus, and compensation. [PDF]

Alzheimers Res Ther
Mitterová K, Výtvarová E, Kovářová A, Lamoš M, Fousek J, Rektorová I.   +5 more
europepmc   +1 more source

Lewy Body Dementia Research in Latin America: A Scoping Review. [PDF]

Mov Disord Clin Pract
Cano-Gutiérrez C, Salazar-Londoño S, Botero-Rodriguez F, Páez-García S, Giraldo S, Santacruz-Escudero JM, Aarsland D, Borda MG, COL‐DLB.   +8 more
europepmc   +1 more source

Version 3 of the Alzheimer Disease Centers’ neuropsychological test battery in the Uniform Data Set (UDS) [PDF]

, 2018
al., et, Morris, John C., Weintraub, Sandra   +2 more
core   +1 more source

Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review. [PDF]

Mol Neurodegener
Bregendahl M, Kaya ZB, Singer W, McLean PJ.   +3 more
europepmc   +1 more source

Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes. [PDF]

Alzheimers Dement
Hannaway N, Zarkali A, Bhome R, Dobreva I, Thomas GEC, Veleva E, Belio IG, Tucker K, Heslegrave A, Zetterberg H, Weil RS.   +10 more
europepmc   +1 more source